| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1084033361 |
| P356 | DOI | 10.1007/S11899-017-0372-3 |
| P698 | PubMed publication ID | 28243848 |
| P2093 | author name string | Joseph Brandwein | |
| Lalit Saini | |||
| P2860 | cites work | Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. | Q54574746 |
| Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter S | Q56959848 | ||
| Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) | Q58414406 | ||
| Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche de | Q79527735 | ||
| Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International | Q33412662 | ||
| Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. | Q34810036 | ||
| Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia | Q35146312 | ||
| Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia | Q35571035 | ||
| Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia | Q35602915 | ||
| The treatment of acute lymphoblastic leukaemia in the elderly. | Q35733310 | ||
| Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study | Q36751420 | ||
| Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL | Q37376595 | ||
| Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study | Q37412290 | ||
| UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia | Q37564762 | ||
| Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease | Q37632798 | ||
| Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy | Q37685601 | ||
| Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: a Canadian consensus | Q38207017 | ||
| Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia | Q38425323 | ||
| Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT. | Q40519372 | ||
| Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia | Q40705613 | ||
| Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia | Q40731204 | ||
| Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia | Q42538832 | ||
| Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. | Q42981949 | ||
| Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol | Q45395583 | ||
| Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis | Q46196747 | ||
| Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome. | Q52856072 | ||
| Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. | Q54348230 | ||
| Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. | Q54372714 | ||
| Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia with imatinib combined with a paediatric-based protocol. | Q54507760 | ||
| P433 | issue | 2 | |
| P921 | main subject | Philadelphia chromosome | Q1129111 |
| P304 | page(s) | 136-142 | |
| P577 | publication date | 2017-02-27 | |
| P1433 | published in | Current hematologic malignancy reports | Q26842233 |
| P1476 | title | New Treatment Strategies for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | |
| P478 | volume | 12 |
| Q61449792 | Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications |
| Q57176106 | BCL2 inhibitor ABT-199 and JNK inhibitor SP600125 exhibit synergistic cytotoxicity against imatinib-resistant Ph+ ALL cells |
| Q47870235 | Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia. |
| Q102372772 | Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia |
Search more.